Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population.
Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population.
复制标题
组织因子途径抑制剂 2 基因多态性与中国人群冠状动脉粥样硬化相关。
DOI：
10.1097/md.0000000000001675
复制
发表时间：
2015-10
期刊：
影响因子：
1.6
通讯作者：
Ni HC
中科院分区：
文献类型：
--
作者：
Yu J;Liu RL;Luo XP;Shi HM;Ma D;Pan JJ;Ni HC
组织因子途径抑制物-2(TFPI-2)可能在动脉粥样硬化的发病机制中发挥重要作用。本研究旨在探讨TFPI-2基因多态性与冠状动脉粥样硬化的关系。407例冠状动脉粥样硬化症患者和306例冠状动脉正常者参加本次研究。采用聚合酶链式反应-直接测序法检测了9个单核苷酸多态性(rs3763473、rs59805398、rs60215632、rs59999573、rs59740167、rs34489123、rs4517、rs4264和rs4271)。采用Gensini评分评价冠状动脉粥样硬化程度。在基线调查后，对冠状动脉粥样硬化患者进行了心血管事件(CVE)发生率的随访。8个SNP符合Hardy-Weinberg平衡，通过连锁不平衡和单倍型分析，构建了8个基于rs59999573、rs59740167和rs34489123的单倍型。两个SNPs(rs59805398和rs34489123)和5个单倍型与冠状动脉粥样硬化相关，即使经Gensini评分调整后也是如此。在随访中(中位数53个月，范围1-60个月)，85名患者发生了CVE。然而，基因多态与CVE的发生没有很强的相关性。组织因子途径抑制物-2基因多态性与中国人群冠状动脉粥样硬化相关，提示组织因子途径抑制物-2基因多态性信息可用于评估冠状动脉粥样硬化的发生风险，但尚无足够的证据表明其能预测血管紧张性心脏病的发生。
Tissue factor pathway inhibitor-2 (TFPI-2) may play critical roles in the pathogenesis of atherosclerosis. In this study, we aimed to investigate the association between TFPI-2 gene polymorphisms and coronary atherosclerosis. Four hundred and seven patients with coronary atherosclerosis and 306 individuals with normal coronary artery were enrolled in the present study. Nine single-nucleotide polymorphisms (SNPs) (rs3763473, rs59805398, rs60215632, rs59999573, rs59740167, rs34489123, rs4517, rs4264, and rs4271) were detected with polymerase chain reaction-direct sequencing method. Severity of coronary atherosclerosis was assessed by Gensini score. After the baseline investigation, patients with coronary atherosclerosis were followed up for incidence of cardiovascular events (CVEs). Eight SNPs were in accordance with the Hardy–Weinberg equilibrium, and 8 haplotypes were constructed based on rs59999573, rs59740167, and rs34489123 after linkage disequilibrium and haplotype analysis. Two SNPs (rs59805398 and rs34489123) and 5 haplotypes correlated with coronary atherosclerosis even after adjustment by Gensini score. At follow-up (median 53 months, range 1–60 months), 85 patients experienced CVE. However, there was no strong association between the gene polymorphisms and the occurrence of CVE. Tissue factor pathway inhibitor-2 gene polymorphisms were associated with coronary atherosclerosis in the Chinese population, suggesting that the information about TFPI-2 gene polymorphisms was useful for assessing the risk of developing coronary atherosclerosis, but there was not enough evidence showing it could predict occurrence of CVE.